Literature DB >> 20061986

Correlation of clinicopathological parameters with HGF, c-Met, EGFR, and IGF-1R expression in uveal melanoma.

Pinar Topcu-Yilmaz1, Hayyam Kiratli, Arzu Saglam, Figen Söylemezoglu, Gülsen Hascelik.   

Abstract

This study evaluated the expression profile of hepatocyte growth factor (HGF), c-Met, epidermal growth factor receptor (EGFR), insulin-like growth factor-1 receptor (IGF-1R), and vitreal and serum EGF, HGF, IGF-1 levels in patients with uveal melanoma and assessed their correlation with the clinicopathological parameters. Forty patients with uveal melanoma were included in the study. Clinicopathological parameters were evaluated with hematoxylin-eosin staining. HGF, c-Met, EGFR, and IGF-1R expressions were evaluated immunohistochemically. HGF, EGF, and IGF-1 levels were measured with enzyme-linked immunosorbent assay in vitreous and serum specimens taken at enucleation and 6 months after the enucleation. HGF, c-Met, IGF-1R, and EGFR expressions were detected in 57.5, 20, 20, and 12.5% of cases, respectively. IGF-1R expression was significantly correlated with the degree of pigmentation, necrosis, and lymphocyte infiltration (P=0.013, 0.04, and 0.017). EGFR expression was significantly correlated with the mitosis rate (P=0.02). Vitreal EGF and serum IGF-1 levels were significantly higher in patients with scleral invasion (15.72+/-29.13, 199.01+/-154.01 pg/ml, respectively) when compared with the patients without invasion (0.56+/-1.05, 33.01+/-36.52 pg/ml) (P=0.03 and 0.015). When the preoperative and postoperative serum growth factor levels were compared, the serum EGF level was found to be lower (125.93+/-62.84, 100.02+/-31.19 pg/ml, P=0.007) and the serum IGF-1 level (165.81+/-153.6, 301.35+/-131.24 pg/ml, P<0.001) was found to be higher in the postoperative 6-month specimens. Uveal melanomas express HGF, c-Met, EGFR, and IGF-1R. Vitreal growth factor levels and expression of EGFR and IGF-1R are correlated with some clinicopathological parameters. IGF-1 and EGF may have a role in the development and progression of uveal melanoma.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20061986     DOI: 10.1097/CMR.0b013e328335a916

Source DB:  PubMed          Journal:  Melanoma Res        ISSN: 0960-8931            Impact factor:   3.599


  19 in total

Review 1.  Melanoma: from mutations to medicine.

Authors:  Hensin Tsao; Lynda Chin; Levi A Garraway; David E Fisher
Journal:  Genes Dev       Date:  2012-06-01       Impact factor: 11.361

2.  Delayed systemic recurrence of uveal melanoma.

Authors:  Nathalie A Kolandjian; Caimiao Wei; Sapna P Patel; Jessica L Richard; Tina Dett; Nicholas E Papadopoulos; Agop Y Bedikian
Journal:  Am J Clin Oncol       Date:  2013-10       Impact factor: 2.339

Review 3.  Insulin-like growth factor system and sporadic malignant melanoma.

Authors:  Ettore Capoluongo
Journal:  Am J Pathol       Date:  2010-12-23       Impact factor: 4.307

Review 4.  Metastatic uveal melanoma: biology and emerging treatments.

Authors:  Scott E Woodman
Journal:  Cancer J       Date:  2012 Mar-Apr       Impact factor: 3.360

5.  Phosphoproteomic screen identifies potential therapeutic targets in melanoma.

Authors:  Kathryn Tworkoski; Garima Singhal; Sebastian Szpakowski; Christina Ivins Zito; Antonella Bacchiocchi; Viswanathan Muthusamy; Marcus Bosenberg; Michael Krauthammer; Ruth Halaban; David F Stern
Journal:  Mol Cancer Res       Date:  2011-04-26       Impact factor: 5.852

6.  Establishment and Characterization of Orthotopic Mouse Models for Human Uveal Melanoma Hepatic Colonization.

Authors:  Shinji Ozaki; Raja Vuyyuru; Ken Kageyama; Mizue Terai; Masahiro Ohara; Hanyin Cheng; Tim Manser; Michael J Mastrangelo; Andrew E Aplin; Takami Sato
Journal:  Am J Pathol       Date:  2015-11-25       Impact factor: 4.307

Review 7.  MET: a promising anticancer therapeutic target.

Authors:  Solange Peters; Alex A Adjei
Journal:  Nat Rev Clin Oncol       Date:  2012-05-08       Impact factor: 66.675

Review 8.  Blood biomarkers for uveal melanoma.

Authors:  Pierre L Triozzi; Arun D Singh
Journal:  Future Oncol       Date:  2012-02       Impact factor: 3.674

9.  Multiplicity: an organizing principle for cancers and somatic mutations.

Authors:  Lewis J Frey; Stephen R Piccolo; Mary E Edgerton
Journal:  BMC Med Genomics       Date:  2011-06-29       Impact factor: 3.063

10.  Myeloid cells: Prime drivers of tumor progression.

Authors:  Benjamin Toh; Benjamin Toh; Jean-Pierre Abastado; Jean-Pierre Abastado
Journal:  Oncoimmunology       Date:  2012-11-01       Impact factor: 8.110

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.